Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN 500 versus BACTOCILL IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN 500 versus BACTOCILL IN PLASTIC CONTAINER.
AUGMENTIN '500' vs BACTOCILL IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin is a semisynthetic aminopenicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting cell wall integrity, leading to bacteriolysis. Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates a broad range of beta-lactamases, preventing degradation of amoxicillin and extending its spectrum to include beta-lactamase-producing bacteria.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity essential for peptidoglycan cross-linking.
1 tablet (amoxicillin 500 mg / clavulanate 125 mg) orally every 8 hours or 1 tablet (amoxicillin 875 mg / clavulanate 125 mg) orally every 12 hours for mild to moderate infections. For severe infections, use 875 mg/125 mg every 12 hours.
1-2 g intravenously every 4 hours.
None Documented
None Documented
Amoxicillin: 1-1.3 hours; clavulanate: 1 hour. In renal impairment (CrCl <30 mL/min): amoxicillin 7-20 hours, clavulanate 4-6 hours. Extends dosing interval.
30-60 minutes (mean 40 min) in adults with normal renal function; prolonged to 7-10 hours in anuria. Clinical context: dosing interval adjustment required in renal impairment.
Renal excretion 50-70% (amoxicillin) and 40-60% (clavulanate) as unchanged drug; tubular secretion and glomerular filtration. Fecal elimination <10%.
Primarily renal (60-70% unchanged by tubular secretion and glomerular filtration); biliary/fecal excretion accounts for <30%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic